A Phase 1, Randomized, Double Blind Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Feb 2017
At a glance
- Drugs ID 93 (Primary) ; ID 93/AP10 602 (Primary) ; ID 93/GLA-SE (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 26 Jan 2017 Planned primary completion date changed from 1 Mar 2017 to 18 Aug 2017.
- 14 Jul 2016 Status changed from recruiting to active, no longer recruiting.